Daiichi Sankyo

Japandaiichi-sankyo.eu

Its roles Owner Operator

project tracked
1
plant
1
news articles
5

Daiichi Sankyo is a global research-driven pharmaceutical company headquartered in Tokyo, Japan. The company discovers, develops, manufactures, and markets prescription medicines, with operations spanning the Americas, Europe, and Asia.

Read more

Its core focus is oncology—particularly antibody-drug conjugates (ADCs) built on its DXd payload and linker platform—alongside cardiovascular and other therapeutic areas. Daiichi Sankyo maintains integrated R&D and GMP manufacturing capabilities covering small molecules, biologics, conjugation, and sterile fill‑finish, supported by quality, regulatory, and supply chain functions. The company collaborates with industry partners on targeted cancer therapies and supplies medicines worldwide. For the chemical and life sciences sector, Daiichi Sankyo is notable for its expertise in complex API synthesis, biologics production, and ADC process development, which combine medicinal chemistry, bioconjugation, and advanced manufacturing to deliver targeted therapeutics.

The project Daiichi Sankyo is involved in

chemXplore tracks 1 project involving Daiichi Sankyo, of which one is active.

Daiichi Sankyo Pfaffenhofen oncology innovation center expansion
  1. Announced / Concept
  2. FEED / Pre-FID
  3. FID / Sanctioned
  4. Under Construction
  5. Commissioning & Start-up
Phase
Under Construction
Where
Germany

Daiichi Sankyo in chemical industry news

25 September 2026
Daiichi Sankyo and Merck withdraw US BLA for ifinatamab deruxtecan in ES‑SCLC

BLA for I‑DXd seeking accelerated approval in extensive‑stage SCLC withdrawn after FDA said Phase 2 data were insufficient; Phase 3 programmes continue.

13 April 2026
Daiichi Sankyo and Merck: FDA Priority Review for Ifinatamab Deruxtecan in ES‑SCLC

BLA for ifinatamab deruxtecan accepted and granted FDA Priority Review for adult ES‑SCLC post‑platinum therapy; PDUFA Oct 10, 2026. Based on IDeate‑Lung01 Phase 2 (B7‑H3 DXd ADC).

19 October 2025
Raludotatug Deruxtecan Shows 50.5% Response in Platinum-Resistant Ovarian Cancer, Reports Daiichi Sankyo and Merck

Raludotatug deruxtecan achieved a 50.5% response rate in phase 2 for platinum-resistant ovarian cancer, with a 5.6 mg/kg dose selected for phase 3.

7 September 2025
Ifinatamab Deruxtecan Shows 48.2% Response in ES-SCLC Phase 2 Trial by Daiichi Sankyo and Merck

Ifinatamab deruxtecan achieved a 48.2% response rate in ES-SCLC patients, with ongoing regulatory discussions and consistent safety profile.

16 February 2024
Daiichi Sankyo Invests €1 Billion to Expand Pfaffenhofen Site into Innovation Center

The Pfaffenhofen site will develop cancer therapies, create 350 jobs by 2030, and enhance ADC technology. The expansion includes new labs, renewable energy use, and collaboration with local partners.

Where its projects are

active all projects

chemXplore Cluster Watch · updated daily
The 16 chemical clusters of Northwest Europe, read as one system
Hydrogen CO2 Oil, gas and chemicals Heat and power
Open the map